Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. Stutterheim J, et al. Among authors: van der schoot ce, van sluis pg. J Mol Diagn. 2012 Mar-Apr;14(2):168-75. doi: 10.1016/j.jmoldx.2011.12.002. Epub 2012 Jan 16. J Mol Diagn. 2012. PMID: 22251610 Free article.
The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
de Haas V, Breunis WB, Dee R, Verhagen OJ, Kroes W, van Wering ER, van Dongen JJ, van den Berg H, van der Schoot CE. de Haas V, et al. Among authors: van dongen jj, van den berg h, van der schoot ce, van wering er. Br J Haematol. 2002 Jan;116(1):87-93. doi: 10.1046/j.1365-2141.2002.03228.x. Br J Haematol. 2002. PMID: 11841400 Free article.
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2002 May;16(5):928-36. doi: 10.1038/sj.leu.2402475. Leukemia. 2002. PMID: 11986956
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. Stutterheim J, et al. Among authors: van noesel mm, van der schoot ce. J Clin Oncol. 2008 Nov 20;26(33):5443-9. doi: 10.1200/JCO.2007.13.6531. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838715
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. Stutterheim J, et al. Among authors: van noesel mm, van der schoot ce. Clin Chem. 2009 Jul;55(7):1316-26. doi: 10.1373/clinchem.2008.117945. Epub 2009 May 21. Clin Chem. 2009. PMID: 19460840 Free article.
355 results